Board approves ESOS 2026 plus new subsidiaries in Mexico and Canada

Corporate Actions View source PDF Explain this filing

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹1490.10

prior close

₹1501.40

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-1.0% vs market

Pharmaceuticals peers, median of 173sector-0.0%-1.3% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.2

15m

-0.4

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3-0.2-1.0-0.0-1.3

Next day

+0.3+0.1+0.2+0.3-0.1

-3.0+0.4-3.4+0.4-3.5

-2.1-0.6-1.5+0.0-2.1

-2.6-1.2-1.4+0.1-2.7

-4.0-0.6-3.4+0.6-4.7

+1.3+0.5+0.8+0.8+0.5

15d

-6.6-0.2-6.3+0.7-7.2

-9.4-1.5-7.9+0.0-9.4

-12.1-8.0-4.1-4.3-7.8

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved ESOS 2026 with 4,72,000 stock options (1% of equity on diluted basis), exercise price up to 50% discount to market. Appointed Shilpa Sharma as Company Secretary and Dr. Viranchi Shah as Independent Director. Also approved incorporating a wholly owned subsidiary in Mexico and a subsidiary (51% or more) in Canada to expand pharma distribution. ESOS needs shareholder approval.

Likely market impact

ESOP may cause minor equity dilution; international expansion signals growth focus. Mildly positive for long-term shareholders.